ERBB2 and neoplasm: In vitro HER2-XPAT protein studies show that XTEN polypeptide masks reduced cytotoxic activity (>4-logs reduction in BT-474 tumor cells) by a much larger magnitude than their effect on target binding (tenfold and sixfold reduction in affinity for human HER2 and CD3, respectively).